Skip to main navigation
TCR² Therapeutics
  • Our Science
  • Our Pipeline
  • Patients
    • Clinical Trials
    • Expanded Access Program
  • Investors
    • Press Releases
    • SEC Filings
  • Get in Touch
  • Join Us
  • Home
  • Our Science
  • Our Pipeline
  • Patients
    ►
      ◄ Back
    • Clinical Trials
    • Expanded Access Program
  • Investors
    ►
      ◄ Back
    • Press Releases
    • SEC Filings
  • Get in Touch
  • Join Us

Investors & Media

Press Releases

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

All News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

Nov 10, 2021

TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 01, 2021

TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity

Oct 25, 2021

TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors

Oct 20, 2021

TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day

Oct 13, 2021

TCR² Therapeutics to Host R&D Day on October 20, 2021

Oct 05, 2021

TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

Sep 17, 2021

TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors

Sep 13, 2021

TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors

Sep 07, 2021

TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Sep 02, 2021

TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »
  • Our Science
  • Our Pipeline
  • Patients
  • Investors
  • Get in Touch
  • Join Us
  • Privacy Policy
  • Disclaimer
  • Terms of Use
  • Supply Terms

© 2023 TCR² Therapeutics. All rights reserved.

TCR² Therapeutics